Nifty
:
25942.10
Sensex
:
84695.54
-100.20 (-0.38%)
-345.91 (-0.41%)
Nifty
Sensex
:
:
25942.10
84695.54
-100.20 (-0.38%)
-345.91 (-0.41%)

Biocon Ltd.

Pharmaceuticals & Drugs - Global

Rating :
62/99

BSE: 532523 | NSE: BIOCON

NSE BSE
395.45
26-Dec-2025
  • Open
  • High
  • Low
  • Previous Close
  •  398.3
  •  401.2
  •  394.05
  •  398.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1962359
  •  778660997.8
  •  424.95
  •  291

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 52,843.49
  • 108.84
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 64,150.09
  • 0.13%
  • 1.97

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.45%
  • 1.63%
  • 12.72%
  • FII
  • DII
  • Others
  • 6.61%
  • 21.24%
  • 3.35%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.38
  • 16.40
  • 10.95

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.74
  • 18.31
  • 7.33

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.72
  • 4.33
  • 29.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 61.15
  • 61.56
  • 51.26

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.47
  • 3.36
  • 2.00

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.20
  • 17.08
  • 13.37

Earnings Forecasts:

(Updated: 27-12-2025)
Description
2024
2025
2026
2027
Adj EPS
8.46
5.1
10.55
14.44
P/E Ratio
46.74
77.54
37.48
27.39
Revenue
15261.7
17513
20573.2
23363.3
EBITDA
3166.3
3632.31
4685.02
5492.41
Net Income
1013.3
602.52
1385.96
1915.01
ROA
1.76
1
2.19
2.9
P/B Ratio
2.19
2.11
1.99
1.77
ROE
4.89
2.65
5.42
7.09
FCFF
1407.6
446.16
2011.64
2676.46
FCFF Yield
2.01
0.64
2.88
3.83
Net Debt
13794.5
10499.2
9834.7
8881.32
BVPS
180.28
187.73
198.5
223.67

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Net Sales
4,295.50
3,590.40
19.64%
3,941.90
3,432.90
14.83%
4,417.00
3,917.10
12.76%
3,821.40
3,953.70
-3.35%
Expenses
3,460.10
2,905.00
19.11%
3,193.00
2,812.50
13.53%
3,338.80
3,001.20
11.25%
3,069.60
3,026.90
1.41%
EBITDA
835.40
685.40
21.89%
748.90
620.40
20.71%
1,078.20
915.90
17.72%
751.80
926.80
-18.88%
EBIDTM
19.45%
19.09%
19.00%
18.07%
24.41%
23.38%
19.67%
23.44%
Other Income
93.00
32.50
186.15%
79.70
1,134.50
-92.97%
36.90
48.60
-24.07%
34.80
565.50
-93.85%
Interest
272.20
225.60
20.66%
276.70
236.00
17.25%
212.40
227.00
-6.43%
223.40
266.70
-16.24%
Depreciation
473.00
419.90
12.65%
455.00
405.40
12.23%
436.30
407.00
7.20%
425.40
414.50
2.63%
PBT
171.30
98.40
74.09%
96.90
1,145.50
-91.54%
486.80
321.70
51.32%
155.90
832.30
-81.27%
Tax
38.50
71.30
-46.00%
7.70
283.70
-97.29%
27.40
96.10
-71.49%
74.80
54.90
36.25%
PAT
132.80
27.10
390.04%
89.20
861.80
-89.65%
459.40
225.60
103.63%
81.10
777.40
-89.57%
PATM
3.09%
0.75%
2.26%
25.10%
10.40%
5.76%
2.12%
19.66%
EPS
0.63
-0.13
-
0.23
5.49
-95.81%
2.87
1.13
153.98%
0.21
5.50
-96.18%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
16,475.80
15,261.70
14,755.70
11,174.20
8,184.00
7,143.10
6,300.50
5,514.40
4,123.40
3,891.10
3,347.40
Net Sales Growth
10.62%
3.43%
32.05%
36.54%
14.57%
13.37%
14.26%
33.73%
5.97%
16.24%
 
Cost Of Goods Sold
5,784.30
5,197.50
4,897.90
3,663.10
2,718.40
2,243.70
1,989.50
1,896.60
1,636.10
1,446.60
1,290.40
Gross Profit
10,691.50
10,064.20
9,857.80
7,511.10
5,465.60
4,899.40
4,311.00
3,617.80
2,487.30
2,444.50
2,057.00
GP Margin
64.89%
65.94%
66.81%
67.22%
66.78%
68.59%
68.42%
65.61%
60.32%
62.82%
61.45%
Total Expenditure
13,061.50
12,243.00
11,559.00
9,054.70
6,691.40
5,841.00
5,043.50
4,390.60
3,294.30
2,911.60
2,584.30
Power & Fuel Cost
-
377.90
388.90
414.80
316.40
270.30
246.10
239.80
189.00
156.40
184.70
% Of Sales
-
2.48%
2.64%
3.71%
3.87%
3.78%
3.91%
4.35%
4.58%
4.02%
5.52%
Employee Cost
-
3,144.40
2,664.10
2,181.00
1,880.10
1,741.00
1,458.80
1,165.30
931.10
747.00
610.10
% Of Sales
-
20.60%
18.05%
19.52%
22.97%
24.37%
23.15%
21.13%
22.58%
19.20%
18.23%
Manufacturing Exp.
-
1,655.90
2,376.90
1,917.20
1,243.50
1,019.20
864.60
721.20
335.70
391.50
203.70
% Of Sales
-
10.85%
16.11%
17.16%
15.19%
14.27%
13.72%
13.08%
8.14%
10.06%
6.09%
General & Admin Exp.
-
948.10
806.00
359.60
181.50
270.50
182.10
53.00
56.80
21.70
144.60
% Of Sales
-
6.21%
5.46%
3.22%
2.22%
3.79%
2.89%
0.96%
1.38%
0.56%
4.32%
Selling & Distn. Exp.
-
649.90
296.60
221.60
243.80
235.90
266.30
277.50
98.20
107.40
100.80
% Of Sales
-
4.26%
2.01%
1.98%
2.98%
3.30%
4.23%
5.03%
2.38%
2.76%
3.01%
Miscellaneous Exp.
-
269.30
128.60
297.40
107.70
60.40
36.10
37.20
47.40
41.00
100.80
% Of Sales
-
1.76%
0.87%
2.66%
1.32%
0.85%
0.57%
0.67%
1.15%
1.05%
1.49%
EBITDA
3,414.30
3,018.70
3,196.70
2,119.50
1,492.60
1,302.10
1,257.00
1,123.80
829.10
979.50
763.10
EBITDA Margin
20.72%
19.78%
21.66%
18.97%
18.24%
18.23%
19.95%
20.38%
20.11%
25.17%
22.80%
Other Income
244.40
1,355.80
967.50
768.10
690.30
605.20
507.50
414.30
206.20
157.10
83.90
Interest
984.70
897.40
974.40
419.00
67.60
57.70
64.90
70.90
61.50
26.00
29.30
Depreciation
1,789.70
1,687.00
1,568.80
1,113.10
814.20
715.10
552.20
447.80
385.10
277.20
248.70
PBT
910.90
1,790.10
1,621.00
1,355.50
1,301.10
1,134.50
1,147.40
1,019.40
588.70
833.40
569.00
Tax
148.40
457.20
227.40
254.10
211.50
221.50
315.10
212.30
156.90
161.60
142.20
Tax Rate
16.29%
24.23%
14.13%
23.88%
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
PAT
762.50
1,013.30
1,022.50
462.70
648.40
819.90
777.10
904.40
351.10
595.80
528.70
PAT before Minority Interest
485.50
1,429.40
1,297.80
643.00
771.60
925.60
899.80
1,001.70
431.80
671.80
587.40
Minority Interest
-277.00
-416.10
-275.30
-180.30
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
PAT Margin
4.63%
6.64%
6.93%
4.14%
7.92%
11.48%
12.33%
16.40%
8.51%
15.31%
15.79%
PAT Growth
-59.70%
-0.90%
120.99%
-28.64%
-20.92%
5.51%
-14.08%
157.59%
-41.07%
12.69%
 
EPS
5.70
7.58
7.65
3.46
4.85
6.13
5.81
6.76
2.63
4.46
3.95

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
21,644.00
19,783.70
17,866.90
8,432.50
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
Share Capital
600.30
600.30
600.30
600.30
600.00
600.00
300.00
300.00
100.00
100.00
Total Reserves
20,618.80
18,863.30
16,992.60
7,628.10
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
Non-Current Liabilities
16,493.30
15,119.80
20,742.30
6,802.70
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
Secured Loans
10,502.50
11,267.70
13,692.30
2,574.30
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
Unsecured Loans
1,902.90
1,664.70
1,598.20
1,424.20
1,469.20
1.40
2.10
2.80
3.90
11.40
Long Term Provisions
260.80
237.60
226.50
91.70
106.20
85.80
66.10
49.30
36.00
29.90
Current Liabilities
14,333.80
15,358.80
8,510.70
3,828.00
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
Trade Payables
6,548.70
6,272.00
3,842.00
1,608.50
1,513.90
1,325.10
1,198.30
1,005.30
739.70
609.80
Other Current Liabilities
3,965.70
6,481.20
1,814.90
1,031.20
1,840.20
1,784.40
1,374.70
870.10
698.20
527.10
Short Term Borrowings
3,454.70
2,149.20
2,480.20
896.00
594.20
667.60
261.20
130.30
97.20
394.90
Short Term Provisions
364.70
456.40
373.60
292.30
261.80
230.90
204.30
135.60
143.20
133.90
Total Liabilities
58,539.60
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
Net Block
31,963.30
30,643.60
29,467.70
6,569.00
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
Gross Block
40,804.30
37,930.10
35,321.40
11,233.00
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
Accumulated Depreciation
8,841.00
7,286.50
5,853.70
4,664.00
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
Non Current Assets
42,253.40
40,574.20
39,407.80
11,718.40
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
Capital Work in Progress
8,508.40
7,993.30
7,317.00
4,110.40
2,800.20
2,196.00
1,898.90
1,302.80
839.20
2,239.50
Non Current Investment
679.70
684.10
742.30
370.20
743.20
108.50
182.50
63.80
188.80
26.80
Long Term Loans & Adv.
870.80
892.50
683.20
483.80
436.40
402.00
335.80
437.20
319.70
350.10
Other Non Current Assets
231.20
360.70
1,197.60
185.00
270.50
73.20
91.00
144.40
176.20
51.00
Current Assets
16,286.20
15,179.20
12,334.00
8,382.30
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
Current Investments
447.30
315.60
1,326.50
1,217.70
1,208.70
857.60
829.30
611.40
1,065.00
874.70
Inventories
4,931.10
4,943.90
4,243.70
2,298.20
1,866.60
1,435.90
1,031.60
722.50
635.30
542.40
Sundry Debtors
5,487.90
6,230.60
3,573.20
2,058.20
1,503.30
1,223.70
1,291.80
1,063.90
883.20
714.50
Cash & Bank
4,120.20
2,258.70
2,400.10
1,747.50
2,015.40
998.60
1,057.20
1,322.80
1,044.30
1,538.60
Other Current Assets
1,299.70
334.40
334.10
660.20
1,006.40
809.20
678.60
428.00
419.90
300.70
Short Term Loans & Adv.
917.00
1,096.00
456.40
400.50
293.30
265.60
153.10
54.70
24.10
134.70
Net Current Assets
1,952.40
-179.60
3,823.30
4,554.30
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
Total Assets
58,539.60
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
4,061.20
2,953.90
1,852.50
1,176.60
1,159.70
1,283.10
1,154.60
662.10
640.00
370.60
PBT
1,886.60
1,525.20
897.10
983.10
1,067.70
870.90
1,002.60
610.00
849.70
751.30
Adjustment
1,711.20
2,356.20
1,685.00
1,245.00
709.60
921.40
472.60
355.70
204.40
42.00
Changes in Working Capital
923.00
-635.20
-501.00
-789.50
-423.80
-165.10
-29.10
-106.50
-211.10
-176.20
Cash after chg. in Working capital
4,520.80
3,246.20
2,081.10
1,438.60
1,353.50
1,627.20
1,446.10
859.20
843.00
617.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-459.60
-292.30
-228.60
-262.00
-193.80
-344.10
-291.50
-197.10
-203.00
-246.50
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-234.10
-1,004.50
-14,281.80
-1,699.10
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
Net Fixed Assets
-393.50
-323.20
-260.40
-284.70
-130.90
744.40
-280.60
-177.90
-215.90
-216.90
Net Investments
-2,064.10
-47.80
-3,990.70
202.20
-456.90
-890.30
107.80
-310.70
-79.30
-3,688.10
Others
2,223.50
-633.50
-10,030.70
-1,616.60
-3,036.90
-1,413.00
-541.00
-195.40
-203.30
2,763.30
Cash from Financing Activity
-1,854.00
-2,332.70
13,048.70
242.10
2,564.00
387.60
-241.70
-239.70
-177.50
1,067.60
Net Cash Inflow / Outflow
1,973.10
-383.30
619.40
-280.40
99.00
111.80
199.10
-261.60
-36.00
296.50
Opening Cash & Equivalents
919.50
1,299.90
653.70
897.00
824.70
659.30
449.00
710.20
757.50
457.50
Closing Cash & Equivalent
2,923.80
919.50
1,294.80
653.70
897.00
824.70
659.30
449.00
710.20
757.50

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
176.73
162.11
146.53
68.53
62.27
54.97
50.17
42.59
39.74
33.10
ROA
2.50%
2.41%
1.79%
4.03%
5.73%
6.94%
9.25%
4.55%
7.64%
7.96%
ROE
7.03%
7.00%
4.98%
9.83%
13.16%
14.26%
18.00%
8.74%
15.37%
16.31%
ROCE
7.43%
7.03%
5.37%
8.30%
11.30%
14.35%
16.11%
8.92%
12.59%
13.93%
Fixed Asset Turnover
0.39
0.41
0.48
0.77
0.74
0.78
0.85
0.73
0.89
1.05
Receivable days
139.43
119.85
91.14
79.19
69.67
72.86
77.96
86.05
74.35
80.16
Inventory Days
117.49
112.31
105.87
92.60
84.38
71.47
58.05
60.00
54.81
53.71
Payable days
450.17
376.86
271.55
209.62
230.92
81.60
81.98
87.98
78.68
71.28
Cash Conversion Cycle
-193.26
-144.70
-74.54
-37.84
-76.87
62.74
54.04
58.07
50.48
62.59
Total Debt/Equity
0.84
0.81
1.01
0.60
0.58
0.40
0.40
0.44
0.48
0.62
Interest Cover
3.10
2.57
3.14
15.54
20.88
19.72
18.12
10.57
33.05
25.90

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Biocon signs out-licensing agreement with Ajanta Pharma
    24th Dec 2025, 12:17 PM

    The company will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries

    Read More
  • Biocon’s arm secures exclusive global rights for Hulio
    23rd Dec 2025, 10:51 AM

    Biocon Biologics will pay a technology license fee and royalties on sales to FKB for a specified tenure

    Read More
  • Biocon gets EIR with VAI status for Biocon Generics Inc facility
    19th Dec 2025, 10:30 AM

    This is based on a cGMP inspection conducted by the agency between the October 6 to October 10, 2025

    Read More
  • Biocon launches GLP-1 peptide, Liraglutide in Netherlands
    15th Dec 2025, 09:59 AM

    The drug-device combination will be marketed in the Netherlands under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management

    Read More
  • Biocon’s arm signs settlement and license agreement with Regeneron, Bayer
    13th Dec 2025, 15:10 PM

    This agreement clears the way for Biocon Biologics to commercialize Yesafili, a biosimilar Aflibercept (40mg/ml), in all countries worldwide

    Read More
  • Biocon’s arm inks pact with Amgen to commercialize Denosumab biosimilars in Europe, ROW
    2nd Dec 2025, 16:12 PM

    The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025

    Read More
  • Biocon’s arm gets voluntary action indicated classification for Bengaluru facility
    27th Nov 2025, 10:36 AM

    Biocon Biologics remains committed to global standards of Quality and Compliance

    Read More
  • Biocon’s arm receives USFDA’s approval for Tofacitinib Extended-Release Tablets
    19th Nov 2025, 12:00 PM

    Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Ulcerative Colitis

    Read More
  • USFDA conducts GMP surveillance Inspection at Biocon’s API facility in Visakhapatnam
    10th Nov 2025, 11:41 AM

    The inspection was concluded with two observations

    Read More
  • Biocon’s arm gets Health Canada approval for Yesintek and Yesintek I.V.
    23rd Oct 2025, 11:49 AM

    Yesintek and Yesintek I.V. are indicated for the treatment of moderate to severe plaque psoriasis in adult patients and in pediatric patients

    Read More
  • Biocon’s arm, Civica expand partnership to launch Insulin Glargine medicine
    17th Oct 2025, 10:00 AM

    The collaboration is to include a new Insulin Glargine medicine that will benefit patients in the United States by increasing supply of high-quality affordable insulins

    Read More
  • Biocon’s arm gets tentative nod for Rifaximin Tablets, 550 mg
    7th Oct 2025, 11:41 AM

    Biocon Pharma in partnership with Carnegie Pharmaceuticals LLC, received tentative approval from USFDA

    Read More
  • Biocon’s arm inks settlement, license pact with Amgen
    1st Oct 2025, 14:12 PM

    Biocon Biologics and Amgen have executed the settlement agreement to resolve the pending patent litigation

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.